The SoFi Technologies, Inc. logo appears on a smartphone screen in this illustration photo in Reno, United States, on December 20, 2024.

SOFI Stock: Hold Or Buy? Jim Cramer Says It’s ‘Too Cheap To Ignore Now’

“It's a bank, guys, and it has a federal charter. It's not going to get replaced by Claude or OpenAI,” Cramer said.

Equity

Nvidia Earnings: What to Watch for on Feb. 25

Key PointsNvidia is set to report earnings after the market closes...

Polymarket, Kalshi Showcase the Power of Prediction Markets

Mention markets are the high-octane, fast-twitch speed competitions of the prediction market world. But they're just one corner of it. Users of Kalshi and its primary rival, Polymarket, can bet on...

<ul class="summary-bullets"><li>Retail sentiment has remained “extremely bullish” on Stocktwits, with message volume surging more than 230% over the past week.</li><li>Speculation intensified after Trump’s “cure for cancer” remark on Monday, made just one day before the SOTU.</li><li>Founder Patrick Soon-Shiong’s presence in Washington added to the buzz, as retail traders tracked his participation in a cancer summit.</li></ul>Shares of ImmunityBio, Inc. (IBRX) hit a fresh four-year high on Tuesday, marking a gain of over 30% so far this week, as retail traders crowded into the stock ahead of U.S. President Donald Trump’s State of the Union address, betting the speech could deliver an unexpected healthcare catalyst.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> jumped 18% on Tuesday and added another 2% after-hours.&nbsp;While the speech is expected to focus heavily on the economy, retail investors in IBRX have zeroed in on a different theme: cancer, drug approvals and the possibility of regulatory reform.<h2 class="st-heading-2">Retail Eyes Trump Speech As IBRX Buzz Swells</h2>On Stocktwits, retail sentiment for IBRX was ‘extremely bullish’ amid a 230% surge in message volumes over the past week.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_791dcf3395.webp" alt="ibrx ss.png" width="972" height="140"><figcaption>IBRX sentiment and message volume as of February 24 | Source: Stocktwits</figcaption></figure>"If I came up with a cure for cancer, they would say 'he should have done it years ago'," Trump said hours before the second State of the Union address of his second term, stoking curiosity from biotech traders. "There is not a thing I can do where these people are going to give me credit."Adding to the intrigue, ImmunityBio founder and executive chairman Patrick Soon-Shiong was in Washington on Tuesday as a featured speaker at the “Cancer 2035: A Roadmap for the Future” summit, co-hosted by the Milken Institute and the Richard Nixon Foundation.&nbsp;One retail investor said they “wouldn’t be surprised” if the president mentions cancer cures during the address, though they doubted he would name specific companies or executives. According to the user, “It’s much better to set ‘cancer cure’ as a priority for his administration than to mention names.”<stembedurl>https://stocktwits.com/mnholdem/message/645788198</stembedurl>Another trader pointed to the timing of Trump’s cancer remark, questioning, “Why [e]specially cancer of all things, and one day before State of the union?” The user noted that Soon-Shiong was still in Washington following a cancer policy summit.<stembedurl>https://stocktwits.com/LB19/message/645787877</stembedurl>A separate post described “rumors” circulating about whether Soon-Shiong might be mentioned during the address, while others tracked his presence in Washington, suggesting his continued stay could signal something brewing.<stembedurl>https://stocktwits.com/Buy_SoFi/message/645787582</stembedurl><stembedurl>https://stocktwits.com/LB19/message/645785697</stembedurl><h2 class="st-heading-2">FDA Reform Hopes Add Fuel To IBRX Trade</h2>Beyond a direct mention, some retail investors are watching for broader policy signals. One user speculated that Trump could speak about streamlining the FDA process to accelerate access to promising drugs, calling it a “jet fuel” for the stock.<stembedurl>https://stocktwits.com/SquiresCollectibles/message/645785829</stembedurl>Another investor argued that highlighting a successful American immunotherapy would align with Trump’s emphasis on innovation and leadership in healthcare. They said, “Supporting a proven promising drug like ANKTIVA would also be a strategic move to appeal to voters, especially those concerned with healthcare and technological progress.”&nbsp;<stembedurl>https://stocktwits.com/phatso/message/645785137</stembedurl>Still, not all traders are convinced the State of the Union needs to deliver fireworks. One post pushed back against the speculation, saying that “The merits of this company and its technology is what is causing this rapid advance in share price.”<stembedurl>https://stocktwits.com/ISEEITALLTHETIME/message/645782674</stembedurl>Others predicted that the stock could “rocket” after the address, regardless of whether specific names are cited.<stembedurl>https://stocktwits.com/GunC/message/645791225</stembedurl><h2 class="st-heading-2">Soon-Shiong’s Trump Talks Add To IBRX Momentum</h2>Trump’s State of the Union comes as he looks to reset the economic narrative ahead of the 2026 midterms, with polls showing pressure on his handling of the economy and a thin 218–214 Republican majority in the House complicating any push for tax cuts.&nbsp;For ImmunityBio, the political lens has been shaped by earlier remarks from Soon-Shiong, who has said&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-rally-not-over-yet-chairman-says-trump-diplomacy-led-to-amazing-results-for-cancer-drug/cZRZDoZR4Dx">discussions with Trump</a> helped accelerate regulatory approvals and global expansion for the company’s cancer immunotherapy, Anktiva.&nbsp;These comments, alongside recent&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-surges-past-4-year-highs-analyst-sees-upside-after-anktiva-s-blowout-growth/cZRvmnGR4zW">regulatory wins</a> across the U.S., U.K., European Union and Saudi Arabia, and strong revenue growth, have reinforced retail interest in the stock. Additionally, H.C. Wainwright on Monday reiterated a ‘Buy’ rating and raised his price target from $15 from $10, citing the removal of regulatory overhangs and expanding commercial reach.IBRX stock has skyrocketed nearly 500% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dr. Patrick Soon-Shiong arrives at Trump National Golf Club Bedminster in Bedminster Township, N.J. on Saturday, Nov. 19, 2016. (Photo by Jabin Botsford/The Washington Post via Getty Images)

IBRX Stock Rallies Into Trump’s Big SOTU Night — Here’s What Traders Think Could Fuel The Next Move

Traders debated whether Trump could reference cancer priorities or FDA reform, with some betting a mention could spark another leg higher for IBRX.

AMD, Zeta Global, MercadoLibre, Tempus AI And Workday: Why These 5 Stocks Are On Investors' Radars Today

AMD, WDAY, ZETA, MELI, TEM were among the stocks seen trending on Tuesday, Feb. 24, 2026.read more...

Top Penny Stocks To Add to Your Watchlist - February 24th

Larimar Therapeutics, Iovance Biotherapeutics, and Mana Capital Acquisition are the three Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced...

Promising Mid Cap Stocks To Watch Now - February 24th

ProShares UltraPro Short QQQ, Arcellx, Hims & Hers Health, Direxion Daily TSLA Bull 2X Shares, and Cipher Mining are the five Mid Cap stocks to watch today, according to MarketBeat's stock screener...

Top Social Media Stocks To Follow Today - February 24th

JOYY, Trump Media & Technology Group, Strive, JOYY, and Blackboxstocks are the five Social Media stocks to watch today, according to MarketBeat's stock screener tool. Social media stocks are shares...

<ul class="summary-bullets"><li>Sellas’ CEO referenced the company’s Phase 3 REGAL trial in a LinkedIn post, following its December update that the final analysis was approaching for GPS as a therapy in AML.</li><li>Anson Funds Management recently disclosed that it held a 4.9% stake in Sellas.</li><li>Last month, Sellas partnered with IMPACT-AML to advance AML treatments.</li></ul>Sellas Life Sciences Group Inc. (SLS) generated significant retail buzz on Monday as the stock shot up more than 15% to its highest levels in more than a month.According to Stocktwits data, message volume on the platform increased nearly 170% over the past 24 hours.<h2 class="st-heading-2">Retail Bullish On Potential Phase 3 REGAL Trial Results</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/SLS">SLS</a> on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/Sellas_jpg_9c62bbaf10.webp" alt="Sellas.jpg">On Sunday, Angelos M. Stergiou, President and CEO of Sellas, made a reference to the company’s Phase 3 REGAL trial in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7431478609229438976/">post</a> on LinkedIn. Last December, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-group-stock-soars-as-it-nears-final-analysis-in-cancer-study/cL7dROARExt">said</a> it was nearing the final analysis from its Phase 3 REGAL trial for Galinpepimut-S (GPS) as a potential maintenance therapy in Acute Myeloid Leukemia (AML).AML is a fast-growing blood and bone marrow cancer in which abnormal white blood cells crowd out healthy cells.One user said the REGAL data was the “ultimate catalyst.”<stembedurl>https://stocktwits.com/kay91667/message/645624253</stembedurl>Another user said that “REGAL Phase 3 remains event-driven and approaching its final trigger.”<stembedurl>https://stocktwits.com/G_Trade/message/645600596</stembedurl>According to an SEC filing last week, Anson Funds Management disclosed that it held a 4.9% stake in the company, prompting a user to call it a “very exciting time” for shareholders.<stembedurl>https://stocktwits.com/Az2fl2025/message/645612860</stembedurl><h2 class="st-heading-2">IMPACT-AML Partnership</h2>Last month, Sellas partnered with IMPACT-AML, a European initiative dedicated to advancing AML treatments, to conduct a multi-site European clinical study of SLS009, the company’s selective CDK9 inhibitor.The stock came under some selling pressure in January over dilution fears after the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-stock-falls-for-fourth-straight-session/cmU2FjBR4dH">said</a> it received about $26.5 million from the exercise of common stock warrants.Year-to-date, SLS shares have gained around 3%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-sw-ip-pkg-stocks-slump-today/cZRtU4BR4yp">Why Did SW, IP, PKG Stocks Slump Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15%

According to Stocktwits data, message volume on the platform surrounding the stock increased nearly 170% over the past 24 hours.

SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as investors react to the ongoing State of the Union address, with community discussion heavily focused on Trump's proposals regarding tariffs and income tax, and divided opinions on whether his remarks will propel the market higher or lead to a reversal.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending due to intense community debate surrounding Donald Trump's State of the Union address, as many speculate whether the speech will ignite a rally, given the stock often acts as a proxy for his political sentiment, or further its decline amid discussions of his legal issues and economic policies.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending with fervent investor discussion surrounding its cancer immunotherapy, ANKTIVA, driven by high expectations for national attention on its groundbreaking treatments and intense speculation about a potential short squeeze that has ignited extreme bullish sentiment.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is actively discussed as the market anticipates potential catalysts from the State of the Union address and NVIDIA's upcoming earnings, driving widespread community speculation on whether these events will lead to a market rally or a significant pullback amidst persistent claims of manipulation.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending on the eve of its highly anticipated earnings report, with the community actively debating whether strong results will propel the broader market higher or trigger a "sell the news" reaction, all while considering a competitor's recent major AI chip deal and ongoing concerns about US-China export policies.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending due to intensified political and regulatory scrutiny on the healthcare sector, including a new bill introduced by senators to break up conglomerates and anticipated negative comments from a former president, sparking a polarized community debate between bearish sentiment and those identifying a long-term buying opportunity.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as recent political commentary underscores the critical need for data centers to secure their own power, a significant bullish catalyst for the company given its extensive renewable energy infrastructure and strategic pivot to AI/HPC. The community is actively discussing high short interest and upcoming earnings, fueling speculation of a potential squeeze.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending following a mixed earnings report, which highlighted revenue growth but wider losses, alongside news of significant layoffs. The community is sharply divided between those anticipating a short squeeze and future product success, and those highlighting persistent cash burn and the potential for further dilution.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA Group is trending following its earnings report, which showcased strong revenue growth and new restaurant openings for fiscal 2025, alongside a positive outlook for fiscal 2026. The community is actively debating its high valuation and moderated same-store sales growth against its aggressive expansion strategy and perceived market share gains over competitors like Chipotle.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending following its Q4 earnings, where cautious fiscal year 2027 subscription revenue guidance, despite an earnings beat, fueled concerns over slowing growth and AI disruption in the enterprise software sector. While many fear AI could replace core services, supporters argue the stock is undervalued, citing its established market position and that AI leaders like Anthropic and OpenAI are Workday customers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
